Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of the Effect of Differing Platelet Transfusion Times in Neonates
The Effect of Variable Platelet Transfusion Durations on Platelet Count in Thrombocytopenic Newborns
Status: Archived
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
434
mi
from 43215
Atlanta, GA
Study of the Effect of Differing Platelet Transfusion Times in Neonates
The Effect of Variable Platelet Transfusion Durations on Platelet Count in Thrombocytopenic Newborns
Status: Archived
Updated: 1/1/1970
Children's Healthcare of Atlanta at Egleston - Pediatric Cardiac Intensive Care Unit
434
mi
from 43215
Atlanta, GA
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase II Study of CLAG Regimen in Combination With Imatinib Mesylate (Gleevec) in Relapsed or Refractory Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
823
mi
from 43215
Tampa, FL
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Canter
1955
mi
from 43215
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
1955
mi
from 43215
Duarte, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
City of Hope Medical Group Inc
1965
mi
from 43215
Pasadena, CA
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
A Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients With Lymphoma
Status: Archived
Updated: 1/1/1970
City of Hope Medical Group Inc
1965
mi
from 43215
Pasadena, CA
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Molecular Breast Imaging (MBI) in Patients With Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), or Lobular Carcinoma In Situ (LCIS)
Evaluation of a Small Field of View Gamma Camera for Scintimammography in Patients With Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, and Lobular Carcinoma In Situ
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
559
mi
from 43215
Rochester, MN
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Children's Doctor
996
mi
from 43215
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Children's Doctor
996
mi
from 43215
Houston, TX
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Emory University
435
mi
from 43215
Atlanta, GA
Intraosseous Infusion of Unrelated Cord Blood Grafts
A Pilot Study of Intraosseous Infusion of Unrelated Cord Blood Grafts
Status: Archived
Updated: 1/1/1970
Emory University
435
mi
from 43215
Atlanta, GA
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Barnes Jewish Hospital - Washington University
397
mi
from 43215
St. Louis, MO
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1
Status: Archived
Updated: 1/1/1970
Barnes Jewish Hospital - Washington University
397
mi
from 43215
St. Louis, MO
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
City of Hope Comprehensive Cancer Center
1955
mi
from 43215
Duarte, CA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Winship Cancer Institute of Emory University
432
mi
from 43215
Egleston, GA
Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
A Phase I Protocol of the Combination Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
Winship Cancer Institute of Emory University
432
mi
from 43215
Egleston, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Sanofi-Aventis Investigational Site Number 840003
432
mi
from 43215
Atlanta, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840003
432
mi
from 43215
Atlanta, GA
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Sanofi-Aventis Investigational Site Number 840002
480
mi
from 43215
New York, NY
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840002
480
mi
from 43215
New York, NY
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Sanofi-Aventis Investigational Site Number 840001
995
mi
from 43215
Houston, TX
Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes
A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients With Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes.
Status: Archived
Updated: 1/1/1970
Sanofi-Aventis Investigational Site Number 840001
995
mi
from 43215
Houston, TX
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
University of California at San Francisco (UCSF)
2109
mi
from 43215
San Francisco, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
University of California at San Francisco (UCSF)
2109
mi
from 43215
San Francisco, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
St. Vincent's Hospital
1972
mi
from 43215
Los Angeles, CA
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/Melphalan/Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma
Status: Archived
Updated: 1/1/1970
St. Vincent's Hospital
1972
mi
from 43215
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
UCLA Orthodpedic Hospital
1974
mi
from 43215
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
UCLA Orthodpedic Hospital
1974
mi
from 43215
Los Angeles, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Uc Irvine Medical Center
1959
mi
from 43215
Orange, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Uc Irvine Medical Center
1959
mi
from 43215
Orange, CA
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
University of Colorado, Boulder
1179
mi
from 43215
Boulder, CO
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
1179
mi
from 43215
Boulder, CO
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Georgetown Univ Med Ctr
325
mi
from 43215
Washington,
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
325
mi
from 43215
Washington,
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
Rush University Medical Center
277
mi
from 43215
Chicago, IL
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
453
mi
from 43215
New Brunswick, NJ
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
University of Medicine and Dentistry - Robert Wood Johnson University Hospital
453
mi
from 43215
New Brunswick, NJ
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
BloodCenter of Wisconsin
330
mi
from 43215
Milwaukee, WI
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Human-cl rhFVIII, a Newly Developed Human Cell-line Derived Recombinant FVIII Concentrate in Previously Treated Patients With Severe Hemophilia A
Status: Archived
Updated: 1/1/1970
BloodCenter of Wisconsin
330
mi
from 43215
Milwaukee, WI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2091
mi
from 43215
Santa Clara, CA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
643
mi
from 43215
Boston, MA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
643
mi
from 43215
Boston, MA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
164
mi
from 43215
Ann Arbor, MI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
164
mi
from 43215
Ann Arbor, MI
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
627
mi
from 43215
St. Joseph, MO
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
481
mi
from 43215
New York, NY
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
481
mi
from 43215
New York, NY
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
127
mi
from 43215
Cleveland, OH
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
910
mi
from 43215
Dallas, TX
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase I, Dose Escalation Study of Plerixafor in Combination With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2005
mi
from 43215
Seattle, WA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence Cancer Center at Providence Hospital
703
mi
from 43215
Mobile, AL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Cancer Center at Providence Hospital
703
mi
from 43215
Mobile, AL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence Portland Cancer Center
2023
mi
from 43215
Portland, OR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Portland Cancer Center
2023
mi
from 43215
Portland, OR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
696
mi
from 43215
Ft. Smith, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
696
mi
from 43215
Ft. Smith, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
624
mi
from 43215
Little Rock, AR
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Alta Bates Comprehensive Cancer Center
2097
mi
from 43215
Berkeley, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Alta Bates Comprehensive Cancer Center
2097
mi
from 43215
Berkeley, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Providence Saint-Joseph Medical Center
1974
mi
from 43215
Burbank, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Providence Saint-Joseph Medical Center
1974
mi
from 43215
Burbank, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Peninsula Medical Center
2108
mi
from 43215
Burlingame, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Peninsula Medical Center
2108
mi
from 43215
Burlingame, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
2036
mi
from 43215
Marysville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
2036
mi
from 43215
Marysville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Cancer Center at Roseville Medical Center
2028
mi
from 43215
Roseville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center at Roseville Medical Center
2028
mi
from 43215
Roseville, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Cancer Center
2042
mi
from 43215
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Cancer Center
2042
mi
from 43215
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
University of California Davis Cancer Center
2042
mi
from 43215
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
2042
mi
from 43215
Sacramento, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
California Pacific Medical Center - California Campus
2109
mi
from 43215
San Francisco, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
California Pacific Medical Center - California Campus
2109
mi
from 43215
San Francisco, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Health - Western Division Cancer Research Group
2109
mi
from 43215
San Rafael, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Health - Western Division Cancer Research Group
2109
mi
from 43215
San Rafael, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Sutter Solano Medical Center
2091
mi
from 43215
Vallejo, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Sutter Solano Medical Center
2091
mi
from 43215
Vallejo, CA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Memorial Hospital
362
mi
from 43215
Chattanooga, TN
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Memorial Hospital
362
mi
from 43215
Chattanooga, TN
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Poudre Valley Hospital
1158
mi
from 43215
Fort Collins, CO
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Poudre Valley Hospital
1158
mi
from 43215
Fort Collins, CO
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
554
mi
from 43215
Hartford, CT
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
554
mi
from 43215
Hartford, CT
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
M. D. Anderson Cancer Center
795
mi
from 43215
Orlando, FL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
M. D. Anderson Cancer Center
795
mi
from 43215
Orlando, FL
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Phoebe Putney Memorial Hospital
582
mi
from 43215
Albany, GA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
Phoebe Putney Memorial Hospital
582
mi
from 43215
Albany, GA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
CCOP - Atlanta Regional
427
mi
from 43215
Atlanta, GA
Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers
Cytogenetic Studies in Leukemia Patients
Status: Archived
Updated: 1/1/1970
CCOP - Atlanta Regional
427
mi
from 43215
Atlanta, GA